secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2026-08-06T20:05:41+00:00
Accession:  0001104659-26-091981
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MetaVia Q2 net loss $5.3M ($0.90/sh); DA-1726 Phase 1 Part 3 all patients at highest doses; topline data Q4 2026
--------------------------------------------------------------------------------

- Net loss of $5.3M ($0.90 per share) for Q2 2026, compared to net loss of $4.0M ($2.87 per share) in Q2 2025.
- Cash and cash equivalents of $12.6M as of June 30, 2026, up from $10.3M at Dec 31, 2025; expects cash to fund operations through 2026.
- All active patients in Phase 1 Part 3 of DA-1726 reached highest planned doses of 48 mg and 64 mg; 16-week topline data expected Q4 2026.
- Presented data at EASL and ADA showing up to 9.1% mean weight loss at 8 weeks on 48 mg dose, with no plateau.
- Planning End-of-Phase 2 meeting with FDA for vanoglipel (DA-1241) in MASH during H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926091981/0001104659-26-091981-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926091981/mtva-20260806x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-091981

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer